A 63-year-old woman with urinary incontinence and progressive gait disorder
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
CASE PRESENTATION
A patient reported fatigue and imbalance for “most of her life.” As a child, she walked more slowly than others and had difficulty ice skating. She noted definite gait impairment about 16 years before presentation and this was more noticeable to her family 13 years before presentation. Since then, she had a slowly progressive gait disorder. She started using a cane 4 years before presentation, a walker 2 years before presentation, and a scooter about 1 year ago. She developed bladder frequency and urge incontinence about 15 years before presentation, which also slowly worsened.
She reported some pain and “dead feeling” in her feet that worsened in the evening and when tired. She had never experienced attack-like worsening or resolution of her neurologic symptoms, and had no history of optic neuritis, brainstem symptoms, or memory impairment. CSF examination 13 years previously was reportedly negative for multiple sclerosis (MS) and tests for adrenomyeloneuropathy and genetic testing for inherited spastic paraparesis were reportedly negative.
Interferon β-1a IM once weekly was started 10 years previously but was discontinued after 1 year for lack of benefit and switched to glatiramer acetate, which the patient remained on for 7 months. She was then treated with mitoxantrone, which was discontinued because of echocardiogram abnormalities, which improved after its discontinuation. Over the previous 1 year, she was receiving monthly IV immunoglobulin G (IVIg) and had received scheduled IV corticosteroids monthly with mild transient symptomatic improvement lasting only 6 months.
She had dry mouth, which was attributed to medication, and occasional mild headaches, but no significant constitutional symptoms or significant travel history. She had a history of tick exposure but had negative Lyme disease testing.
She had had a hysterectomy for benign tumor with deep venous thrombosis following surgery, prior sinus and lumbar surgery, and hyperlipidemia. Her medications …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Alert Me
Recommended articles
-
Clinical/Scientific Notes
Novel GBE1 mutation in a Japanese family with adult polyglucosan body diseaseYasuo Harigaya, Takashi Matsukawa, Yukio Fujita et al.Neurology: Genetics, February 24, 2017 -
Clinical Implications of Neuroscience Research
Glycogen metabolismMetabolic coupling between astrocytes and neuronsEduardo E. Benarroch et al.Neurology, March 15, 2010 -
Clinical/Scientific Notes
Phosphorylation prevents polyglucosan transport in Lafora diseaseJean-Marie Girard, Scellig S.D. Stone, Hannes Lohi et al.Neurology, May 23, 2012 -
Resident and Fellow Section
Teaching NeuroImages: Prominent spinal cord atrophy and white matter changes in adult polyglucosan body diseaseA. Sebastian López Chiriboga et al.Neurology, May 15, 2017